Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3

3(37.5%)

N/A

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 3(3)

N/A(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT04230187Phase 3Recruiting

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Role: lead

NCT04215731Phase 3Recruiting

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

Role: lead

NCT06779474Not Yet Recruiting

Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

Role: lead

NCT06900686Completed

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Role: lead

NCT06898359Completed

Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer

Role: lead

NCT06883084Enrolling By Invitation

Clinical Relevance of Pathologic Regression IN Lymph Node for Locally Advanced Rectal Cancer

Role: lead

NCT06879197Completed

Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer

Role: lead

NCT05360277Phase 2Recruiting

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

Role: lead

NCT06147492Not ApplicableCompleted

Urinary Retention Following taTME VS laTME Total Mesorectal Excision for Rectal Cancer

Role: lead

NCT06143605Completed

Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors

Role: lead

NCT05450029Phase 2Recruiting

Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer

Role: lead

NCT05427669Phase 3Not Yet Recruiting

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)

Role: lead

NCT05201872Unknown

Bacteriological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Role: lead

NCT05201885Recruiting

Oncological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer.

Role: lead

NCT03629132Not ApplicableUnknown

PRP Prevents Recurrence of Intrauterine Adhesions

Role: lead

NCT03548844Not ApplicableUnknown

Local Excision Versus Total Mesorectal Excision In Pathological Complete Response (ypT0-1cN0) Mid- Or Low-Rectal Cancer After Neoadjuvant Therapy

Role: lead

All 16 trials loaded